Colgate-Palmolive Company (CL) Stock Price, Analysis & Valuation 2026
TradingView provides the price chart; its market feed and observation time may differ from the FMP snapshot.
Colgate-Palmolive Company (CL): analysis summary
Market snapshot
FMP · 5 Nov 2026 ↗- Market cap
- $78.45B
- Analyst consensus target
- $101.00+2.3% vs quote
-0.1% session change
Financial highlights
FMP · 5 Nov 2026 ↗- Annual revenue
- $20.38B+1.4% annual growth
- Dividend yield
- 2.1%Trailing twelve months
- Next earnings
- 2027-01-29Schedule may change
- FMP DCF estimate
- $133.41+35.2% vs quote
- Fundamental score
- 3.4/10
Investment view
Colgate-Palmolive Company presents a valuation tradeoff. The analyst target implies a change of +2.3% from the dated quote, suggesting a limited potential return based on current consensus. Annual revenue grew +1.4% over the comparable annual period. The question for investors is whether this modest top-line expansion can translate into stronger earnings and cash generation. Subsequent results need to demonstrate how this revenue growth converts into improved profitability and free cash flow.
Market and valuation data: Financial Modeling Prep, saved 5 Nov 2026. Price observation: 5 Nov 2026, 21:00 UTC. Editorial update: 5 Nov 2026, 22:46 UTC. Model inputs have their own retrieval time. DCF and analyst targets are separate estimates, not guaranteed outcomes. Sources and reporting periods.
Related stocks to explore alongside CL
Colgate-Palmolive Company (CL) financial profile
The screener fundamental score for CL is 3.4/10, based equally on financial health, profitability and growth, plus revisions when available.
Revisions is the strongest component at 4.8/10; growth is the weakest at 2.6/10. This describes the operating profile, not whether the share price is attractive.
Our calculation: contribution of each pillar
How Colgate-Palmolive Company reaches 3.4/10
(3.1 + 3.2 + 2.6 + 4.8) ÷ 4 = 3.4/10. Each available component has equal weight; the display uses the same JavaScript rounding as the screener.
Swipe to see all columns
| Component | Score | Weight | Points / 10 |
|---|---|---|---|
| Financial health | 3.1/10 | 25.00% | 0.775 |
| Profitability | 3.2/10 | 25.00% | 0.800 |
| Growth | 2.6/10 | 25.00% | 0.650 |
| Revisions | 4.8/10 | 25.00% | 1.200 |
Source: saved Alert Invest stock-detail API component scores, retrieved 5 Nov 2026, 22:48 UTC. Revisions contribute when available; valuation remains separate from this average. The original component scores are retained in the saved API response; no unavailable underlying financial inputs are inferred.
The fundamental score equally averages financial health, profitability and growth, plus revisions when available. All three operating components are required. This is not an investment recommendation.
Fundamental score: 3.4/10 · input coverage: 100.0%. Retrieved 5 Nov 2026, 22:48 UTC. Screener data source. These dates may differ from the FMP market snapshot.
About Colgate-Palmolive Company (CL)
Operating globally, Colgate-Palmolive Company and its affiliated entities are engaged in the production and distribution of a diverse range of consumer goods.
More about Colgate-Palmolive Company
Its operations are structured into two primary divisions: Oral, Personal and Home Care, and Pet Nutrition. The Oral, Personal and Home Care division encompasses a broad array of offerings, spanning oral hygiene (e.g., toothpastes, toothbrushes, mouthwashes), personal care (e.g., bar and liquid soaps, shower gels, shampoos, conditioners, deodorants, antiperspirants, skin health items), and home care solutions (e.g., dishwashing detergents, fabric conditioners, household cleaners).
These products are distributed through various channels, including traditional and online retailers, wholesalers, and distributors, under well-known brand names such as Colgate, Darlie, elmex, hello, meridol, Sorriso, Tom's of Maine, Irish Spring, Palmolive, Protex, Sanex, Softsoap, Lady Speed Stick, Speed Stick, EltaMD, Filorga, PCA SKIN, Ajax, Axion, Fabuloso, Murphy, Suavitel, Soupline, and Cuddly. Furthermore, this segment supplies specialized pharmaceutical products to dentists and other professionals in oral healthcare.
Conversely, the Pet Nutrition segment focuses on providing specialized pet food. This includes everyday nutritional options marketed under the Hill's Science Diet brand, as well as therapeutic diets designed to assist in managing various health conditions in dogs and cats, sold under the Hill's Prescription Diet brand.
Distribution for these pet nutrition items occurs via pet supply stores, veterinary clinics, and online retail platforms. Established in 1806, Colgate-Palmolive Company maintains its corporate headquarters in New York, New York.
Colgate-Palmolive Company (CL) valuation & price targets
FMP reports an analyst target of $101.00 and a DCF estimate of $133.41, against the dated share price of $98.69. Analyst targets and DCF use different assumptions; the gap alone does not establish which is more reliable.
The DCF is a model estimate, while the analyst target is a consensus forecast. These are different measures, not guaranteed fair values.
| Measure | Value | Change vs quote | Interpretation |
|---|---|---|---|
| Analyst consensus target | $101.00 | +2.34% | External analyst target; not an intrinsic-value estimate |
| FMP DCF estimate | $133.41 | +35.18% | Provider cash-flow model; depends on its assumptions |
| P/E · TTM | 38.34x | Not applicable | Price relative to trailing earnings |
| P/B · TTM | 273.80x | Not applicable | Price relative to book equity |
| P/S · TTM | 3.69x | Not applicable | Price relative to trailing revenue |
| FCF yield · TTM | 4.83% | Not applicable | Trailing free cash flow relative to market value |
Valuation calculations and definitions
| Measure | Value | Definition |
|---|---|---|
| Analyst consensus target | $101.00 | FMP price-target-consensus; not a prediction by Alert Invest |
| Change to analyst target | +2.34% | (target / observed price − 1) × 100 |
| FMP DCF estimate | $133.41 | Third-party model estimate; assumptions require review |
| Change from price to DCF | +35.18% | (DCF / observed price − 1) × 100 |
| Price premium/discount to DCF | -26.03% | (observed price / DCF − 1) × 100 |
Source: FMP quote, price-target-consensus and discounted-cash-flow endpoints; calculations use the dated quote. A lower earnings multiple alone does not establish undervaluation. These measures use different assumptions and are not a buy or sell recommendation.
Analyst price target range
FMP reports a low analyst target of $95.00 and a high target of $112.00. These are external price expectations, not outcome probabilities.
- Earnings or cash-flow growth falling below expectations.
- A lower valuation multiple as growth expectations or discount rates change.
- Business and regulatory risks to verify in the latest company filings.
- Consensus price target: $101.00.
- Return calculated from the same dated quote as the other cards.
- Annual EPS consensus: 3.92 for the period ending 2026-12-31 (provider reporting units).
- Earnings and cash-flow delivery exceeding the reference expectations.
- Sustained profitability while funding investment needs.
- A valuation multiple consistent with stronger expected growth.
The risk and upside checks are general valuation conditions, not the documented reasoning of individual analysts or a model deriving these targets. Rating percentages are not scenario probabilities.
Analyst consensus and rating distribution
- Analyst consensus: Hold
- 46 available ratings
The gauge shows the share of Buy and Strong Buy ratings. See the full rating distribution →
Source: FMP ratings. Analyst sentiment is not a probability of gains or an Alert Invest recommendation.
Source: FMP grades-consensus at the saved retrieval date. Rating distribution and price targets are separate datasets. The rating count is not asserted to be the number of target-price contributors.
Full rating distribution
Sources for this section
Financial Modeling Prep · updated 5 Nov 2026, 22:46 UTC
CL key statistics & financial profile
Valuation
| Metric | Value | Signal |
|---|---|---|
| P/E · TTM | 38.3x | Reference metric |
| P/B · TTM | 273.8x | Reference metric |
| P/S · TTM | 3.7x | Reference metric |
| DCF estimate | $133.41 | Below DCF estimate |
Profitability
| Metric | Value | Signal |
|---|---|---|
| Gross margin · TTM | 60.6% | High margin |
| Net margin · TTM | 9.6% | Positive margin |
| ROE · TTM | 1,135.8% | High return |
| ROA · TTM | 12.3% | High return |
| ROIC · TTM | 30.1% | High return |
Balance sheet
| Metric | Value | Signal |
|---|---|---|
| Debt / equity · TTM | 26.8x | High debt |
| Current ratio · TTM | 1.0x | Low liquidity |
| Market capitalization | $78.45B | Reference metric |
Growth, cash flow & dividends
| Metric | Value | Signal |
|---|---|---|
| Annual revenue | $20.38B | Reference metric |
| Annual revenue growth | +1.4% | Modest growth |
| Free cash flow yield · TTM | 4.8% | Positive FCF yield |
| Dividend yield · TTM | 2.1% | Reference metric |
Data: FMP. TTM = trailing twelve months. Annual revenue period ends 2025-12-31. Sources, dates and calculations →
How to read these signals
These fixed reference bands are separate from the fundamental score and are not sector rankings or buy/sell recommendations. Bar lengths identify the reference band (85%, 55% or 50%, and 20% or 15%); they are not probabilities or additional model scores.
Debt/equity: low 0–0.5, moderate above 0.5–1.5, high above 1.5; negative equity requires review. Current ratio: strong at 2 or above, adequate at 1–2, low below 1. FCF yield: high at 5% or above, positive above zero. Gross margin: high at 40% or above, mid-range at 20–40%. Net margin: high at 20% or above. ROE and ROIC: high at 15% or above; ROA at 5% or above; otherwise positive or non-positive. Revenue growth: growing at 10% or above, modest at 0–10%, declining below zero. DCF compares the provider estimate with the dated quote. Other figures are shown without a strength judgement. These bands may be unsuitable for some industries.
Sources for this section
Financial Modeling Prep · updated 5 Nov 2026, 22:46 UTC
Price trend · exponential moving averages
The daily close is above all available averages, a positive alignment across the measured horizons. It does not establish overvaluation. The exponential moving average (EMA) weights recent prices more heavily than older prices, making it responsive to current trends. It is a backward-looking indicator and does not predict future price movements or intrinsic value.
+5.1% · close above EMA
+7.7% · close above EMA
+10.4% · close above EMA
Blue line: daily close; dashed amber line: EMA. Source: FMP daily EMA endpoint. The latest daily observation may still be provisional during the session. Each percentage compares that session’s close with its EMA, not the separate quote above. Exponential averages give greater weight to recent prices; they are lagging indicators, not price forecasts. Method and source →
CL: additional technical context
Additional technical indicators
These indicators complement the fundamental assessment; they do not change the screener’s fundamental score.
The 50-session SMA averages the daily closes equally. On 2026-11-05, it stood at USD 90.03; the same-session close was 9.6% above it. This describes price positioning, not intrinsic value or a future return.
Indicator documentation →The 50-session WMA assigns greater linear weight to recent closes. On 2026-11-05, it stood at USD 91.43; the same-session close was 7.9% above it. This describes price positioning, not intrinsic value or a future return.
Indicator documentation →The 50-session DEMA combines exponential averages to reduce lag. On 2026-11-05, it stood at USD 93.34; the same-session close was 5.7% above it. This describes price positioning, not intrinsic value or a future return.
Indicator documentation →The 50-session TEMA combines multiple exponential averages to reduce lag further. On 2026-11-05, it stood at USD 94.87; the same-session close was 4.0% above it. This describes price positioning, not intrinsic value or a future return.
Indicator documentation →The 14-session RSI was 65.7 on 2026-11-05, between the conventional lower and upper thresholds. RSI compares the strength of recent price gains and losses on a zero-to-one-hundred scale; the usual reference levels are 30 and 70. An extreme reading can persist and is not by itself a reversal signal.
Indicator documentation →The 20-session standard deviation of daily prices was USD 2.75 on 2026-11-05. It describes dispersion of prices around their rolling average in price units. It is neither an annualised return-volatility percentage nor a forecast of the next price move.
Indicator documentation →Williams %R was -23.2 over 14 sessions on 2026-11-05. The oscillator locates the close within the recent high-to-low range: readings nearer zero are closer to the upper end and readings nearer minus one hundred to the lower end. This positioning does not establish that a reversal will follow.
Indicator documentation →The 14-session ADX was 40.8 on 2026-11-05. It measures the strength of a trend, not whether prices are rising or falling. Direction cannot be established from ADX alone; this reading is not a buy or sell instruction.
Indicator documentation →Source: FMP daily technical-indicator endpoints, with the observation date stated in each explanation. The latest session may be provisional. Different look-back windows measure different features of prices.
Colgate-Palmolive Company (CL) earnings and forecasts
2027-01-29
Earnings and annual forecasts
| Item | Date / period | EPS |
|---|---|---|
| Next scheduled earnings in available dataset | 2027-01-29 | 0.98 |
| Latest reported earnings in available dataset | 2026-10-30 | 0.97 |
| Nearest future annual estimate | 2026-12-31 | 3.92 |
Source: FMP earnings and analyst-estimates endpoints; see source timestamps below. EPS uses provider reporting units, which may differ from the quote currency. Estimated dates and forecasts can change. An absent future event is not replaced by a past date.
Sources for this section
Financial Modeling Prep · updated 5 Nov 2026, 22:46 UTC
CL insider filings
The 12 displayed records include 0 priced purchases and 0 priced sales. Unpriced awards and other acquisitions are excluded from these totals.
Acquisitions can include awards, gifts or other non-purchase events. Only transaction codes P and S are labelled purchases and sales; missing prices are not valued at zero. No directional investment signal is inferred.
| Date | Name | Classification | Shares | Price (USD) | Value (USD) | Filing URL |
|---|---|---|---|---|---|---|
| 2026-10-01 | NORRINGTON LORRIE M | Other / unclassified | 300.00 | $87.42 | $26,226.00 | SEC filing |
| 2026-10-01 | Newman Brian | Other / unclassified | 214.00 | $87.42 | $18,707.88 | SEC filing |
| 2026-10-01 | BILBREY JOHN P | Other / unclassified | 271.00 | $87.42 | $23,690.82 | SEC filing |
| 2026-09-16 | Wallace Noel R. | Other / unpriced transaction | 29,649.00 | $0.00 | Not available | SEC filing |
| 2026-09-16 | Wallace Noel R. | Other / unclassified | 205,197.00 | $87.02 | $17,856,242.94 | SEC filing |
| 2026-09-16 | GRANT SHANE | Other / unpriced transaction | 7,355.00 | $0.00 | Not available | SEC filing |
| 2026-09-16 | GRANT SHANE | Other / unclassified | 50,902.00 | $87.02 | $4,429,492.04 | SEC filing |
| 2026-09-16 | Tsourapas Panagiotis | Other / unclassified | 31,814.00 | $87.02 | $2,768,454.28 | SEC filing |
| 2026-09-16 | Tsourapas Panagiotis | Other / unpriced transaction | 4,597.00 | $0.00 | Not available | SEC filing |
| 2026-09-16 | SUTULA STANLEY J III | Other / unpriced transaction | 8,045.00 | $0.00 | Not available | SEC filing |
| 2026-09-16 | SUTULA STANLEY J III | Other / unclassified | 55,674.00 | $87.02 | $4,844,751.48 | SEC filing |
| 2026-09-16 | Hazlin John | Other / unclassified | 27,042.00 | $87.02 | $2,353,194.84 | SEC filing |
Sources for this section
Financial Modeling Prep · updated 5 Nov 2026, 22:46 UTC
Recent CL news in the available dataset
No recent news supplied for this snapshot.
Sources for this section
Financial Modeling Prep · updated 5 Nov 2026, 22:46 UTC
Sources, calculations and methodology
Alert Invest calculates the displayed valuation gaps from a dated Financial Modeling Prep quote and provider estimates. The fundamental score uses the saved screener API scores for financial health, profitability and growth, plus revisions when available, with equal weight; company research retains its own reporting period. This is a dated snapshot, not a live quote service. Missing metrics remain unavailable and do not receive a score. No AI-generated quotation or investment recommendation is added.
Financial Modeling Prep · SEC EDGAR
Data sources & dates
Financial data: Financial Modeling Prep
Price observed: 5 Nov 2026, 21:00 UTC
Annual revenue period ended: 2025-12-31
Last data refresh: 5 Nov 2026, 22:47 UTC
TTM figures cover trailing twelve months; reporting windows may differ. Scoring methodology.
The Alert Invest fundamental profile
The fundamental score equally averages financial health, profitability and growth, plus revisions when available, on a 0–10 scale to one decimal place. Component scores come directly from the same stock-detail API as the screener, with the same rounding rule. All three operating components must be available. Missing revisions are excluded rather than scored as zero.
What the radar includes
Revisions is a fourth axis for earnings-expectation context. When available, it has the same weight as each operating component in the fundamental total. Valuation is assessed separately through multiples, the provider DCF estimate and analyst targets; it is not included in this score. The separate Alert Invest trading score is also a different measure.
Value and growth research
A high fundamental score does not establish that a stock is undervalued. Compare business profitability, financial resilience and growth with the price paid; the valuation section keeps those questions separate. Published investor principles and disclosed holdings provide research leads, not extra score points or evidence of endorsement.
Source: the Alert Invest screener stock-detail API. Its component scores are supplied by the app; this page does not reconstruct missing underlying ratios. Scores reflect the saved API observation and can change when the screener refreshes. The score is a research aid, not a recommendation or a forecast of returns.
Annual revenue is labelled by statement end date. TTM metrics are provided by FMP; retrieval time is not the accounting-period end. Valuation estimates are not guarantees.
Questions about CL
What price is shown for CL?
$98.69, observed 5 Nov 2026, 21:00 UTC. This is a dated snapshot, not a live quote.
What is the analyst price target for CL?
FMP reports $101.00. The change from the observed quote is +2.34%. This is not a guaranteed return.
What is the P/E ratio for CL?
The supplied TTM P/E is 38.34x. A low or negative multiple alone is not proof of undervaluation.
When are the next CL earnings?
The next future date in the supplied dataset is 2027-01-29. Check company investor relations for confirmation.
What dividend information is available for CL?
The supplied TTM dividend yield is 2.14%. The next future payment date in the available dataset is 2026-11-13. Missing data does not establish that no dividend is paid.
Sources for this section
Financial Modeling Prep · updated 5 Nov 2026, 22:46 UTC
Follow the research
Explore the portfolio and membership benefits, or follow Alert Invest on X.
For informational purposes only. Not investment advice.